Here are 1-3 brief analogies for Twist Bioscience:

• Like a specialized manufacturer such as **Intel** or **TSMC**, but they "print" synthetic DNA on silicon chips for biological applications instead of computer chips.
• **Seagate** or **Western Digital**, but for storing digital information within DNA.
• The "Intel Inside" of synthetic biology, providing the core DNA building blocks for drug discovery and other research applications.

• Synthetic genes: Custom-made DNA sequences for research and development.
• Tools for sample preparation: Products designed to prepare biological samples for advanced analysis.
• Antibody libraries: Collections of diverse antibodies used in the discovery and development of new therapeutic drugs.
• DNA as a digital data storage medium: Utilizing synthetic DNA to store digital information.

Twist Bioscience (TWST) primarily sells its synthetic DNA-based products and services to other companies and research institutions.

Based on the provided information, its major customers and collaboration partners include:

• Victorian Clinical Genetic Services
• Vivlion GmbH
• Kyowa Kirin Co., Ltd. (TYO: 4151)
• deepCDR Biologics AG
• Centogene N.V (NASDAQ: CNTG)
• Boehringer Ingelheim International GmbH

Emily Leproust, CEO, Co-Founder & Board Member

Emily Leproust is the CEO and a co-founder of Twist Bioscience, which she established in 2013. She is recognized as a pioneer in high-throughput DNA synthesis. Before co-founding Twist Bioscience, Dr. Leproust held various escalating positions at Agilent Technologies, including Director of Applications and Chemistry R&D for Genomics, where she was instrumental in architecting the successful SureSelect product line and developing the Oligo Library Synthesis technology. She is also a co-founder of Petri, an accelerator dedicated to startups in engineering and biology.

Adam Laponis, Chief Financial Officer

Adam Laponis serves as the Chief Financial Officer for Twist Bioscience.

Patrick Finn, President and Chief Operating Officer

Patrick Finn was promoted to President and Chief Operating Officer of Twist Bioscience in October 2022, having joined the company in 2015. Prior to this role, he served as Chief Commercial Officer starting in 2019 and as Vice President of Sales and Marketing upon joining in 2015. Dr. Finn previously held the position of Vice President of Sales at Enzymatics (which was later acquired by QIAGEN), where he oversaw commercial activities for North America and Europe. His extensive career also includes leadership roles at Agilent Technologies as Director of Business Development, Director of Product Development for Beckman Coulter, and various technical positions at Invitrogen and GE Healthcare/Amersham International.

Siyuan Chen, Chief Technology Officer

Siyuan Chen holds the position of Chief Technology Officer at Twist Bioscience.

Angela Bitting, Chief ESG Officer, Senior Vice President of Corporate Affairs

Angela Bitting is the Chief ESG Officer and Senior Vice President of Corporate Affairs at Twist Bioscience.

1. Persistent Unprofitability and High Cash Burn: Twist Bioscience has not yet achieved profitability, consistently reporting net operating losses and requiring significant capital to fund its operations and scale its proprietary platform. Despite strong revenue growth, the company faces substantial cash burn, which is a key financial concern for investors.
2. Technological and Competitive Risk: The synthetic biology and DNA synthesis markets are characterized by rapid technological advancements. Twist Bioscience's proprietary silicon-based DNA synthesis platform, while a significant competitive advantage, faces the ongoing risk of disruption from new, potentially more cost-effective or efficient technologies being developed by competitors or academic groups (e.g., enzymatic or nanopore-based DNA synthesis). The company operates in a highly competitive landscape against established players with greater resources and extensive intellectual property portfolios, such as GenScript, Integrated DNA Technologies (IDT), Thermo Fisher Scientific, Eurofins Scientific, and Danaher's IDT. Intellectual property challenges are also an existential risk in this high-stakes market.
3. Market Adoption and Execution Challenges in Emerging Areas: Twist Bioscience is expanding into nascent and high-potential markets such as DNA data storage and biopharma drug discovery. While these represent significant growth opportunities, they also carry inherent risks related to the speed of market adoption, the company's ability to effectively execute its strategy in these complex fields, and the extensive investment required for research and development. For example, the widespread adoption of DNA data storage still faces hurdles related to cost and speed.

Twist Bioscience (TWST) operates in several key addressable markets for its synthetic DNA-based products and services:

Synthetic DNA and Synthetic Biology

• The global DNA synthesis market size was estimated at USD 3.52 billion in 2024 and is projected to reach USD 13.85 billion by 2033, growing at a CAGR of 16.89% from 2025 to 2033.
• Another estimate values the global DNA synthesis market size at US$ 5.42 billion in 2025, growing to US$ 6.37 billion in 2026, and projected to reach around US$ 27.03 billion by 2035 at a CAGR of 17.42% between 2026 and 2035.
• The global synthetic DNA market was valued at US$3.7 billion in 2024 and is projected to reach US$10.3 billion by 2030, growing at a CAGR of 18.7% from 2024 to 2030.
• The U.S. DNA synthesis market size was estimated at USD 1.25 billion in 2024 and is projected to reach USD 4.62 billion by 2033, expanding at a CAGR of 15.93% from 2025 to 2033.
• North America held the largest share of the global DNA synthesis market, with approximately 39.83% in 2024.
• The broader global synthetic biology market size was valued at USD 25.6 billion in 2025 and is set to expand to USD 128.1 billion by 2035, advancing at a 17.5% CAGR from 2026 to 2035. North America is the largest market for synthetic biology.

Tools for Sample Preparation (Genomics)

• The global sample preparation market size was estimated at USD 7.88 billion in 2024 and is projected to reach USD 11.27 billion by 2030, growing at a CAGR of 6.1% from 2025 to 2030.
• Another report states the global sample preparation market size was valued at approximately USD 7.35 billion in 2024 and is predicted to reach around USD 13.41 billion by the end of 2034, expanding at a CAGR of around 6.2% from 2025 to 2034.
• North America was the largest region in the sample preparation market in 2025. The U.S. sample preparation market is primarily driven by advancements in biopharmaceutical research, drug discovery, and clinical diagnostics.
• The genomics segment dominated the sample preparation market in 2024, with a share of 30.94%, and is expected to witness the fastest growth rate.
• The global NGS (Next-Generation Sequencing) sample preparation market size is projected to reach USD 11,774.7 million by 2033, with a CAGR of 15.8% from 2025 to 2033. The U.S. NGS sample preparation market size is USD 1063.1 million in 2025 and is predicted to evolve at a CAGR of 14% over the analysis period.

Antibody Libraries for Drug Discovery and Development

• The global antibody library technology market is anticipated to reach a size of US$ 1.7 billion by 2025. It is set to showcase a CAGR of 4.1% during the forecast period to attain a value of US$ 2.2 billion by 2032.
• Another estimate for the global antibody library technology market is US$ 165.7 million in revenue in 2024, expected to expand at a CAGR of 3.98%, reaching an estimated valuation of US$ 217.8 million by the end of 2031.
• The global antibody discovery market size was valued at USD 6.9 billion in 2022 and is projected to reach USD 17.2 billion by 2032, growing at a CAGR of 9.6% from 2023 to 2032.
• The global human combinatorial antibody libraries market size is calculated at US$ 116.2 million in 2024, grew to US$ 122 million in 2025, and is projected to reach around US$ 189.57 million by 2034, expanding at a CAGR of 5.04% between 2025 and 2034. North America dominates the human combinatorial antibody libraries market in 2024.

DNA as a Digital Data Storage Medium

• The global DNA data storage market was valued at USD 145.8 million in 2025. The market is expected to grow from USD 272.8 million in 2026 to USD 6.3 billion in 2031 and USD 80.2 billion in 2035, at a value CAGR of 88% during the forecast period.
• Another estimate projects the global DNA data storage market to reach USD 44,213.05 million by 2034, growing at a CAGR of 88.01% from 2025 to 2034.
• The U.S. DNA data storage market was valued at USD 44.9 million in 2025. The U.S. is the largest single national market for DNA data storage.
• Twist Bioscience spun out its DNA data storage division into an independent company, Atlas Data Storage, in May 2025.

Here are 3-5 expected drivers of future revenue growth for Twist Bioscience (symbol: TWST) over the next 2-3 years:

1. Expansion in AI-driven Drug Discovery and Biopharma Services: Twist Bioscience anticipates significant revenue growth from increased demand in the therapeutic sector, particularly from customers engaged in AI-enabled drug discovery and development. Orders from customers working on AI discovery projects grew by over $25 million in fiscal 2024, and the company continues to see strong demand from customers building models or testing molecules using its DNA synthesis and protein solutions.
2. Growth in Next-Generation Sequencing (NGS) Applications, especially Minimal Residual Disease (MRD) Testing: The company expects continued growth in its NGS applications, driven by demand from liquid biopsy and rare disease diagnostics. The commercial launch of new products such as MRD Express in early calendar 2026, with planned commercial scaling into 2027, is anticipated to be a significant contributor to revenue. Additionally, Twist is launching new library preparation kits like the TrueAmp library prep kit and PCR-Free WGS Library Preparation Kit to expand its reach in the whole genome sequencing market and address challenging sample types for clinical research.
3. Expansion of Served Addressable Market (SAM) through New Product Introductions and Market Diversification: Twist Bioscience aims to expand its served addressable market from $7 billion to $12 billion by 2030 through the introduction of new products and solutions. This includes entering new market segments with GMP-grade products, focusing on the RNA segment, and exploring new market opportunities such as AgBio. The company is also launching new plasmid preps to support nucleic acid therapeutics research.
4. Increased Customer Acquisition and Diversification: Twist Bioscience is actively working to expand its customer base and diversify its revenue streams. Efforts include leveraging its Express Genes portfolio to gain traction within the academic market and shifting its sales emphasis beyond solely large pharmaceutical accounts. This strategy has resulted in an influx of net new customers and is designed to build a broader and more resilient customer base.

Share Repurchases

• Twist Bioscience repurchased common stock valued at $4.0 million in 2024.
• The company's common stock repurchases amounted to $4.4 million in 2023.
• Share repurchases totaled $7.8 million in 2022.

Share Issuance

• Twist Bioscience issued $269.8 million in common stock during 2022.
• The company also issued $323.9 million in common stock in 2021.
• The number of shares outstanding has shown a consistent increase over the past several years, growing by 2.93% in the last year alone.

Outbound Investments

• Twist Bioscience's "Purchase of investments" totaled $51.9 million in 2024.
• "Purchase of investments" amounted to $76.3 million in 2023.
• The company's "Purchase of investments" reached $217.6 million in 2022, and net acquisitions were $13.9 million in the same year.

Capital Expenditures

• Capital expenditures for Twist Bioscience were $5.1 million in 2024.
• The company's capital expenditures were $27.8 million in 2023.
• In 2022, capital expenditures reached $101.9 million and are primarily focused on expanding and enhancing its proprietary silicon-based DNA synthesis platform and manufacturing processes.